| |  Online-Ressource |
|---|
| Verfasst von: | Bozorgmehr, Farastuk [VerfasserIn]  |
|---|
| | Christopoulos, Petros [VerfasserIn] |
|---|
| | Chung, Inn [VerfasserIn] |
|---|
| | Cvetkovic, Jelena [VerfasserIn] |
|---|
| | Feißt, Manuel [VerfasserIn] |
|---|
| | Krisam, Johannes [VerfasserIn] |
|---|
| | Schneider, Marc [VerfasserIn] |
|---|
| | Heußel, Claus Peter [VerfasserIn] |
|---|
| | Kreuter, Michael [VerfasserIn] |
|---|
| | Müller, Daniel W. [VerfasserIn] |
|---|
| | Thomas, Michael [VerfasserIn] |
|---|
| | Rieken, Stefan [VerfasserIn] |
|---|
| Titel: | Protocol of the TREASURE study |
|---|
| Titelzusatz: | Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease$da randomized, open-label, multicenter phase II trial |
|---|
| Verf.angabe: | Farastuk Bozorgmehr, Petros Christopoulos, Inn Chung, Jelena Cvetkovic, Manuel Feißt, Johannes Krisam, Marc A. Schneider, Claus Peter Heußel, Michael Kreuter, Daniel W. Müller, Michael Thomas and Stefan Rieken |
|---|
| E-Jahr: | 2022 |
|---|
| Jahr: | 24 September 2022 |
|---|
| Umfang: | 9 S. |
|---|
| Fussnoten: | Gesehen am 18.10.2022 |
|---|
| Titel Quelle: | Enthalten in: BMC cancer |
|---|
| Ort Quelle: | London : BioMed Central, 2001 |
|---|
| Jahr Quelle: | 2022 |
|---|
| Band/Heft Quelle: | 22(2022), Artikel-ID 1011, Seite 1-9 |
|---|
| ISSN Quelle: | 1471-2407 |
|---|
| Abstract: | Recently, the combination of the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab with first-line chemotherapy has demonstrated to improve outcome for patients with advanced small cell lung cancer (SCLC), leading to approval of this regimen. At the same time, accumulating (pre-)clinical data suggest synergisms of radiotherapy and immunotherapy via the radiation-mediated induction of anti-tumor immunogenicity. Combining the recent findings, the TREASURE trial aims at further enhancing response to upfront chemo-immunotherapy by the addition of thoracic radiotherapy (TRT). |
|---|
| DOI: | doi:10.1186/s12885-022-10074-9 |
|---|
| URL: | kostenfrei: Volltext: https://doi.org/10.1186/s12885-022-10074-9 |
|---|
| | kostenfrei: Volltext: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-022-10074-9 |
|---|
| | DOI: https://doi.org/10.1186/s12885-022-10074-9 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Anti-PD-L1 monoclonal antibody |
|---|
| | Atezolizumab |
|---|
| | Extensive disease small cell lung cancer |
|---|
| | First-line therapy |
|---|
| | Radioimmuntherapy |
|---|
| | SCLC |
|---|
| | Thoracic radiotherapy |
|---|
| K10plus-PPN: | 1819114813 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
| |
|
|---|
| | |
|---|
| Lokale URL UB: |  Zum Volltext |
|---|
Protocol of the TREASURE study / Bozorgmehr, Farastuk [VerfasserIn]; 24 September 2022 (Online-Ressource)
